Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment

Author(s): Ning Liu, Hao Fang, Yanling Li, Wenfang Xu

Journal Name: Current Medicinal Chemistry

Volume 16 , Issue 36 , 2009

Become EABM
Become Reviewer


It is well known that cyclins and cyclin-dependent kinases (CDKs) play essential roles in regulation of the cell cycle. In past two decades, the scientific researches suggest that the cyclin D1/ CDK4 complex is a key regulator of the transition through the G1 phase of the cell cycle. Moreover, deregulation of the cyclin D /CDK4 pathway has been identified in multiple tumor types. Thus, CDK4 is a genetically validated therapeutic target; hence, there has been a surge of interests in finding selective CDK4 inhibitors as anti-cancer agents. This review will give the recent progress in the studies of structure, functions of CDK4 and highly selective and potent CDK4 inhibitors.

Keywords: Cell cycle, G1-phase, cyclin-dependent kinases, CDK4, tumor, selective inhibitors, anti-cancer agents

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [4869 - 4888]
Pages: 20
DOI: 10.2174/092986709789909611
Price: $65

Article Metrics

PDF: 13